Effects of Different Gonadotropin Preparations in GnRH Antagonist Protocol for Patients with Polycystic Ovary Syndrome During IVF/ICSI: a Retrospective Cohort Study

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2024 Feb 27

PMID 38410698

Authors

Zhengyan Hu

Rujun Zeng

Rui Gao

Mingli Chen

Xiumei Liu

Qiong Zhang

Lang Qin

Xun Zeng

Affiliations

Soon will be listed here.

Abstract

Purpose: To compare the effects of recombinant FSH alfa (rFSH-alfa), rFSH-beta, highly purified human menopausal gonadotropin (HP-hMG) and urinary FSH (uFSH) in women with polycystic ovarian syndrome who have undertaken the GnRH antagonist protocol during IVF/ICSI treatment.

Method: A single-center retrospective cohort study including women with PCOS who received the GnRH antagonist protocol from January 2019 to July 2022 was conducted. Patients were divided into rFSH-alfa group, HP-hMG group, uFSH group, and rFSH-beta group, and the number of oocytes retrieved, clinical pregnancy rate of the fresh cycle (primary outcomes), embryo quality, and severe OHSS rate (secondary outcomes) were compared.

Results: No statistical differences were found among the four groups in fresh cycle clinical pregnancy rate (p=0.426), nor in the subgroup analyses. The HP-hMG group had a smaller number of oocytes retrieved and a higher high-quality D3 embryo rate than the three FSH groups (p<0.05). No statistical differences were found among the four groups in the severe OHSS rate (p=0.083).

Conclusion: For women with PCOS undergoing the GnRH antagonist protocol, the clinical pregnancy rates of fresh IVF/ICSI-ET cycle are similar for all four types of Gn. With a lower risk of OHSS and a similar number of high-quality and available embryos, HP-hMG may have an advantage in the PCOS population.

Citing Articles

Fixed versus flexible gonadotropin releasing hormone antagonist protocol in women with polycystic ovary syndrome undergoing in vitro fertilization: An RCT.

Fatehi H, Davar R, Nikfarjam E, Bayati F Int J Reprod Biomed. 2024; 22(8):617-626.

PMID: 39494117 PMC: 11528296. DOI: 10.18502/ijrm.v22i8.17230.

References

Ji J, Liu Y, Tong X, Luo L, Ma J, Chen Z . The optimum number of oocytes in IVF treatment: an analysis of 2455 cycles in China. Hum Reprod. 2013; 28(10):2728-34. DOI: 10.1093/humrep/det303. View

Bahadur G, Homburg R, Jayaprakasan K, Raperport C, Huirne J, Acharya S . Correlation of IVF outcomes and number of oocytes retrieved: a UK retrospective longitudinal observational study of 172 341 non-donor cycles. BMJ Open. 2023; 13(1):e064711. PMC: 9809223. DOI: 10.1136/bmjopen-2022-064711. View

Costello M, Misso M, Balen A, Boyle J, Devoto L, Garad R . Evidence summaries and recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome: assessment and treatment of infertility. Hum Reprod Open. 2019; 2019(1):hoy021. PMC: 6396642. DOI: 10.1093/hropen/hoy021. View

Teede H, Tay C, Laven J, Dokras A, Moran L, Piltonen T . Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023; 108(10):2447-2469. PMC: 10505534. DOI: 10.1210/clinem/dgad463. View

Bordewijk E, Mol F, van der Veen F, van Wely M . Required amount of rFSH, HP-hMG and HP-FSH to reach a live birth: a systematic review and meta-analysis. Hum Reprod Open. 2019; 2019(3):hoz008. PMC: 6561325. DOI: 10.1093/hropen/hoz008. View

Smitz J, Andersen A, Devroey P, Arce J . Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients. Hum Reprod. 2006; 22(3):676-87. DOI: 10.1093/humrep/del445. View

. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2003; 19(1):41-7. DOI: 10.1093/humrep/deh098. View

Magnusson A, Kallen K, Thurin-Kjellberg A, Bergh C . The number of oocytes retrieved during IVF: a balance between efficacy and safety. Hum Reprod. 2017; 33(1):58-64. DOI: 10.1093/humrep/dex334. View

Lambalk C, Banga F, Huirne J, Toftager M, Pinborg A, Homburg R . GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update. 2017; 23(5):560-579. DOI: 10.1093/humupd/dmx017. View

10.

Weiss N, Kostova E, Nahuis M, Mol B, van der Veen F, van Wely M . Gonadotrophins for ovulation induction in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019; 1:CD010290. PMC: 6353048. DOI: 10.1002/14651858.CD010290.pub3. View

11.

Pena J, Chang P, Zeitoun K, Thornton 2nd M, Sauer M . Supraphysiological estradiol levels do not affect oocyte and embryo quality in oocyte donation cycles. Hum Reprod. 2002; 17(1):83-7. DOI: 10.1093/humrep/17.1.83. View

12.

Lunenfeld B, Bilger W, Longobardi S, Alam V, DHooghe T, Sunkara S . The Development of Gonadotropins for Clinical Use in the Treatment of Infertility. Front Endocrinol (Lausanne). 2019; 10:429. PMC: 6616070. DOI: 10.3389/fendo.2019.00429. View

13.

Fanton M, Cho J, Baker V, Loewke K . A higher number of oocytes retrieved is associated with an increase in fertilized oocytes, blastocysts, and cumulative live birth rates. Fertil Steril. 2023; 119(5):762-769. DOI: 10.1016/j.fertnstert.2023.01.001. View

14.

Wolfenson C, Groisman J, Couto A, Hedenfalk M, Cortvrindt R, Smitz J . Batch-to-batch consistency of human-derived gonadotrophin preparations compared with recombinant preparations. Reprod Biomed Online. 2005; 10(4):442-54. DOI: 10.1016/s1472-6483(10)60819-x. View

15.

La Marca A, Sunkara S . Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update. 2013; 20(1):124-40. DOI: 10.1093/humupd/dmt037. View

16.

Jia R, Liu Y, Jiang R, Zhu X, Zhou L, Chen P . The Optimal Number of Oocytes Retrieved From PCOS Patients Receiving IVF to Obtain Associated With Maximum Cumulative Live Birth Rate and Live Birth After Fresh Embryo Transfer. Front Endocrinol (Lausanne). 2022; 13:878214. PMC: 9259927. DOI: 10.3389/fendo.2022.878214. View

17.

van Wely M, Kwan I, Burt A, Thomas J, Vail A, van der Veen F . Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev. 2011; (2):CD005354. PMC: 7388278. DOI: 10.1002/14651858.CD005354.pub2. View

18.

Fleming R, Seifer D, Frattarelli J, Ruman J . Assessing ovarian response: antral follicle count versus anti-Müllerian hormone. Reprod Biomed Online. 2015; 31(4):486-96. DOI: 10.1016/j.rbmo.2015.06.015. View

19.

Kadoura S, Alhalabi M, Nattouf A . Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis. Sci Rep. 2022; 12(1):4456. PMC: 8924277. DOI: 10.1038/s41598-022-08400-z. View

20.

McCartney C, Marshall J . CLINICAL PRACTICE. Polycystic Ovary Syndrome. N Engl J Med. 2016; 375(1):54-64. PMC: 5301909. DOI: 10.1056/NEJMcp1514916. View